DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1963)

Pulmonary Hypertension | Landscape & Forecast | Disease Landscape & Forecast

Pulmonary Hypertension | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable, driven by the premium price that may be charged for PH agents. Commercial interest in PH is high as a result of recent and significant advances in the understanding of its etiology and pathophysiology and the emergence of new therapies to treat the disease.


United States, EU5, Japan

Key Drugs Covered:

Uptravi, Orenitram, Adempas, Opsumit, Adcirca, Tracleer, Revatio, Letairis/Volibris, Remodulin, Flolan, Veletri, Tyvaso, Ventavis, Beraprost, ralinepag, esuberaprost, bardoxolone methyl, inhaled dry powder treprostinil, INOpulse

Key Companies Mentioned:

Actelion · United Therapeutics · Bayer Healthcare · GlaxoSmithKline · Gilead Sciences · Pfizer · Arena Pharmaceuticals · Mannkind Corporation · Bellerophon Therapeutics · Liquidia Technologies · Reata Pharmaceuticals

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • November 2018
      • September 2018
      • August 2018
      • June 2018
      • March 2018
    • Market Outlook
      • Key Findings
        • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Pulmonary Hypertension?
        • What Factors Are Constraining the Market for Pulmonary Hypertension?
      • Drug-Class-Specific Trends
        • Endothelin Receptor Antagonists
        • Phosphodiesterase-Type 5 Inhibitors
        • Prostacyclin Analogues
        • Soluble Guanylate Cyclase Stimulators
        • Antioxidant Inflammation Modulators
    • Forecast
      • Market Forecast Assumptions - PAH
      • Market Forecast Dashboard - PAH
      • Market Forecast Assumptions - CTEPH
      • Market Forecast Dashboard - CTEPH
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Disease Overview
        • Pulmonary Arterial Hypertension (PAH)
        • Pulmonary Hypertension Due to Left Heart Disease (PH-LHD)
        • Pulmonary Hypertension Due to Lung Disease
        • Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
        • Pulmonary Hypertension with Unclear Multifactorial Mechanisms
        • Key Pathways and Drug Targets
    • Epidemiology Overview
      • Key Findings
        • Key Findings
      • Epidemiology Populations
        • Diagnosed Prevalent Cases of Pulmonary Hypertension (All Causes)
        • Diagnosed Prevalent Cases of Pulmonary Arterial Hypertension
        • Diagnosed Prevalent Cases of Pulmonary Hypertension Due to Left Heart Disease
        • Diagnosed Prevalent Cases of Pulmonary Hypertension Due to Lung Diseases and/or Hypoxia
        • Diagnosed Prevalent Cases of Chronic Thrombotic and/or Embolic Disease
        • Diagnosed Prevalent Cases of Pulmonary Hypertension Due to Inoperable Chronic Thrombotic and/or Embolic Pulmonary Hypertension
        • Diagnosed Pulmonary Hypertension Due to Miscellaneous Causes
        • Diagnosed Prevalent Cases of Pulmonary Arterial Hypertension by Functional Class
        • Drug-Treated Cases of Pulmonary Arterial Hypertension
    • Current Treatment Overview
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Endothelin Receptor Antagonists
        • PDE-5 Inhibitors
        • Prostacyclin Analogues
        • Soluble Guanylate Cyclase Stimulators
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Country/Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Pulmonary Hypertension
    • Emerging Therapies Overview
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Pulmonary Arterial Hypertension
        • Prostacyclin Analogues
        • Nitric Oxide
        • Antioxidant Inflammation Modulators
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Pulmonary Hypertension
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Pulmonary Hypertension Bibliography

Already a Client? Log in to access this report.

  • Pub Date: November 2018
  • Author(s): David Rees, Ph.D; Dr. Ravdeep Kaur, MPH
  • David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.

  • Ravdeep Kaur started working in Decision Resources Inc. as an associate epidemiologist since December 31 st , 2015. She performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. She produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. She holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from Rajiv Gandhi University of Health Sciences, India. She also has a Fellowship in Heath care Technology Assessment from World health Organization (WHO), India office.  Prior to joining Decision Resources, Ravdeep worked as a Consultant in Reproductive, Maternal, Child and Adolescent Health Program in a United States Agency for International development (USAID) funded project.   

Purchase Report

Recent reports:
You may also be interested in: